Dextromethorphan/quinidine sulfate for pseudobulbar affect

Drugs of Today

Volumn 44, Issue 9, 2008, Pages 661-668

  Rosen, Howard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS QUINIDINE SULFATE; FLUOXETINE; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; PHENOTHIAZINE; PIMOZIDE; PLACEBO; QUINIDINE SULFATE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANXIETY; BLEEDING; BLURRED VISION; BRAIN STEM; CENTER FOR NEUROLOGIC STUDY LABILITY SCALE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTION; FATALITY; FOOD AND DRUG ADMINISTRATION; FRONTAL LOBE; GAIT DISORDER; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPONATREMIA; LIBIDO DISORDER; LIMBIC SYSTEM; LOW DRUG DOSE; MENTAL INSTABILITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PANIC; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHING AND CRYING SCALE; PATHOLOGICAL LAUGHTER; PATHOPHYSIOLOGY; PR INTERVAL; PSEUDOBULBAR AFFECT; QT INTERVAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; URINE RETENTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS AS TOPIC; DEXTROMETHORPHAN; DRUG COMBINATIONS; HUMANS; PSEUDOBULBAR PALSY; QUINIDINE; SEROTONIN UPTAKE INHIBITORS;

EID: 57649120887     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.9.1258664     Document Type: Review

References (40)

1. Lawson, I.R., MacLeod, R.D. The use of imipramine (" Tofranil") and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969, 115(520): 281-5.
2. House, A., Dennis, M., Molyneux, A., Warlow, C., Hawton, K. Emotionalism after stroke. BMJ 1989, 298(6679): 991-4.
3. Dark, F.L., McGrath, J.J., Ron, M.A. Pathological laughing and crying. Aust N Z J Psychiatry 1996, 30(4): 472-9.
4. Lieberman, A., Benson, D.F. Control of emotional expression in pseudobulbar palsy. A personal experience. Arch Neurol 1977, 34(11): 717-9.
5. Darwin, C. The Expression of Emotions in Man and Animals. New York: Appleton and Company, 1872.
6. Wilson, S.A.K. Some problems in neurology: No. 2 pathological laughing and crying. J Neurol Psychopathol 1924, 4(16): 299-333.
7. Gallagher, J.P. Pathologic laughter and crying in ALS: A search for their origin. Acta Neurol Scand 1989, 80(2): 114-7.
8. Zeilig, G., Drubach, D.A., Katz-Zeilig, M., Karatinos, J. Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj 1996, 10(8): 591-7.
9. Schiffer, R., Pope, L.E. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005, 17(4): 447-54.
10. Kim, J.S., Choi, S., Kwon, S.U., Seo, Y.S. Inability to control anger or aggression after stroke. Neurology 2002, 58(7): 1106-8.
11. Poeck, K. Pathophysiology of emotional disorders associated with brain damage. Handb Clin Neurol 1969, 3: 343-67.
12. Kim, J.S., Choi-Kwon, S. Poststroke depression and emotional incontinence: Correlation with lesion location. Neurology 2000, 54(9): 1805-10.
13. Andersen, G., Ingeman-Nielsen, M., Vestergaard, K., Riis, J.O. Pathoanatomic correlation between post-stroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994, 25(5): 1050-2.
14. Achari, A.N., Colover, J. Posterior fossa tumors with pathological laughter. JAMA 1976, 235(14): 1469-71.
15. Wisoff, J.H., Epstein, F.J. Pseudobulbar palsy after posterior fossa operation in children. Neurosurgery 1984, 15(5): 707-9.
16. Tel, H., Sakamoto, Y. Pontine infarction due to basilar artery stenosis presenting as pathological laughter. Neuroradiology 1997, 39(3): 190-1.
17. Bhatjiwale, M.G., Nadkarni, T.D., Desai, K.I., Goel, A. Pathological laughter as a presenting symptom of massive trigeminal neuromas: Report of four cases. Neurosurgery 2000, 47(2): 469-71; discussion 471-2.
18. Parvizi, J., Anderson, S.W., Martin, C.O., Damasio, H., Damasio, A.R. Pathological laughter and crying: A link to the cerebellum. Brain 2001, 124(Pt. 9): 1708-19.
19. Arciniegas, D.B., Lauterbach, E.C., Anderson, K.E. et al. The differential diagnosis of pseudobulbar affect (PEA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr 2005, 10(5): 1-14; quiz 15-6.
20. Robinson, R.G., Parikh, R.M., Lipsey, J.R., Starkstein, S.E., Price, T.R. Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993, 150(2): 286-93.
21. Moore, S.R., Gresham, L.S., Bromberg, M.B., Kasarkis, E.J., Smith, R.A. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997, 63(1): 89-93.
22. Nahas, Z., Arlinghaus, K.A., Kotrla, K.J., Clearman, R.R., George, M.S. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998, 10(4): 453-5.
23. Allman, P., Hope, R.A., Fairburn, C.G. Emotionalism following brain damage: A complex phenomenon. Postgrad Med J 1990, 66(780): 818-21.
24. Cummings, J.L., Arciniegas, D.B., Brooks, B.R. et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006, 11(6 Suppl. 6): 1-7.
25. Kim, S.W., Shin, I.S., Kim, J.M., Lim, S.Y., Yang, S.J., Yoon, J.S. Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuropharmacol 2005, 28(5): 249-51.
26. Udaka, F., Yamao, S., Nagata, H., Nakamura, S., Kameyama, M. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984, 41(10): 1095-6.
27. Wolf, J.K., Santana, H.B., Thorpy, M. Treatment of "emotional incontinence" with levodopa. Neurology 1979, 29(10): 1435-6.
28. Ramasubbu, R. Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003, 26(5): 233-5.
29. Schiffer, R.B., Herndon, R.M., Rudick, R.A. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985, 312(23): 1480-2.
30. Murai, T., Barthel, H., Berrouschot, J., Sorger, D., von Cramon, D.Y., Muller, U. Neuroimaging of serotonin transporters in post-stroke pathological crying. Psychiatry Res 2003 123(3): 207-11.
31. Seliger, G.M., Hornstein, A., Flax, J., Herbert, J., Schroeder, K. Fluoxetine improves emotional incontinence. Brain Inj 1992, 6(3): 267-70.
32. Andersen, G., Vestergaard, K., Riis, J.O. Citalopram for post-stroke pathological crying. Lancet 1993, 342(8875): 837-9.
33. Burns, A., Russell, E., Stratton-Powell, H., Tyrell, P. O'Neill, P., Baldwin, R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999, 14(8): 681-5.
34. Brooks, B.R., Thisted, R.A., Appel, S.H. et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology 2004, 63(8): 1364-70.
35. Panitch, H.S., Thisted, R.A., Smith, R.A. et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006, 59(5): 780-7.
36. Zhang, Y., Britto, M.R., Valderhaug, K.L., Wedlund, P.J., Smith, R.A. Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992, 51(6): 647-55.
37. Palmer, G.C. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001, 2(3): 241-71.
38. Collier, T.L., Waterhouse, R.N., Kassiou, M. Imaging sigma receptors: Applications in drug development. Curr Pharm Des 2007, 13(1): 51-72.
39. Su, T.P., Hayashi, T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003, 10(20): 2073-80.
40. Kamel, H., Kameyama, T., Nabeshima, T. Effects of sigma receptor ligands on conditioned fear stress. Methods Find Exp Clin Pharmacol 1998, 20(7): 613-8.